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Abstract
Joint diseases are conditions with an often progressive and generally painful nature affecting the patient’s quality of life and, in some cases, requ-
iring a prompt diagnosis in order to start the treatment urgently. Synovial fluid (SF) laboratory testing is an important part of a diagnostic evalua-
tion of patients with joint diseases. Laboratory testing of SF can provide valuable information in establishing the diagnosis, be a part of a patient’s 
follow-up and treatment with the purpose of improving the patient’s health and quality of life. 
Synovial fluid laboratory testing is rarely performed in Croatian medical biochemistry laboratories. Consequently, procedures for SF laboratory te-
sting are poorly harmonized. This document is the second in the series of recommendations prepared by the members of the Working group for 
extravascular body fluid samples of the Croatian Society of Medical Biochemistry and Laboratory Medicine. It addresses preanalytical, analytical, 
and postanalytical issues and the clinical significance of tests used in SF laboratory testing with the aim of improving the value of SF laboratory te-
sting in the diagnosis of joint diseases and assisting in the achievement of national harmonization. It is intended for laboratory professionals and all 
medical personnel involved in synovial fluid collection and testing.
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Chronic rheumatic conditions comprise more than 
150 different diseases (including joint disease) with 
an often progressive and generally painful nature. 
They are among the leading causes of morbidity 
and disability worldwide and represent an enor-
mous burden on healthcare systems (1). 
Joint disease is often accompanied by alterations 
in the composition and volume of synovial fluid 
(SF). Laboratory testing of the SF can contribute to 
the differential diagnosis of rheumatic conditions 
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accompanied with joint effusions. Indications for 
SF laboratory testing include inflamed joints with 
a known or unknown aetiology, suspected acute 
prosthetic joint infection, as well as infection iden-
tification by microbiological analyses and diagnos-
ing crystal-induced arthritis, etc. Distinguishing 
amongst non-inflammatory and inflammatory 
joint effusions is considered the most important 
clinical application of SF laboratory testing. Fur-
thermore, the clinical significance of SF laboratory 
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testing has been established in acute arthritis, es-
pecially in the diagnosis of septic and crystal ar-
thritis, as well as intercritical gout. Laboratory test-
ing of SF can provide valuable information in es-
tablishing the diagnosis of a rheumatic condition, 
be a part of patient’s follow-up and treatment with 
the purpose of improving the patient’s health and 
quality of life (2-5). 
The Working group for extravascular body fluid 
samples (WG EBFS) of the Croatian Society of Med-
ical Biochemistry and Laboratory Medicine (CSM-
BLM) conducted an extensive survey aimed at 
mapping critical areas in the preanalytical, analyti-
cal, and postanalytical phases of extravascular 
body fluids analysis in Croatia. The main results 
demonstrated that SF laboratory testing is rarely 
performed in Croatian medical biochemistry labo-
ratories, and since the procedures used in other in-
vestigated extravascular body fluid testing are not 
harmonized, the same level of harmonization 
might be expected in SF laboratory testing (6). 
These results, combined with a thorough review 
and critical assessment of all available scientific ev-
idence, were used to design this document. 
This recommendation is the second in the series of 
recommendations prepared by the members of 
the WG EBFS of the CSMBLM (7). It addresses the 
preanalytical, analytical, and postanalytical issues 
and clinical significance of tests used in SF analysis 
with the aim of improving the value of SF labora-
tory testing in the diagnosis of joint diseases and 
assisting in the achievement of national harmoni-
zation of SF testing. The ultimate goal is to im-
prove patient safety and healthcare outcomes. 
This document is intended for laboratory profes-
sionals and all medical personnel involved in the 
synovial fluid collection and analysis. It is organ-
ized in sections referring to the preanalytical, ana-
lytical and postanalytical phases of SF laboratory 
testing. Specific recommendations are presented 
in a box at the beginning of each section, followed 
by explanations and data derived from relevant lit-
erature. Similar to the first WG EBFS’s recommen-
dation dedicated to serous fluids laboratory test-
ing, cytological and microbiological testing are 
beyond the scope of this document since they are 
not performed in Croatian medical biochemistry 
laboratories (7).
1. Synovial fluid
Movable (diarthrodial) joints are enclosed in syno-
vial cavities called synovia, which are filled with a 
viscous synovial fluid, produced by the ultrafiltra-
tion of plasma through the synovial membrane 
(and its adjacent capillaries) with the incorporation 
of hyaluronic acid secreted by synoviocytes. Syno-
vial fluid glucose and uric acid concentrations re-
semble that of plasma, while its protein concentra-
tion is much lower compared to plasma protein 
concentrations. Synovial fluid also contains high 
amounts of locally synthesized hyaluronic acid, 
which contributes to the fluid’s viscosity. The main 
functions of SF are to lessen the friction between 
joints facilitating their free movement, to provide 
nutrients to the metabolically active and vascular-
deficient cartilage, and to remove waste metabo-
lites.
Physiologically, only small volume of SF (up to 
about 3.5 mL) is present in the synovium. Condi-
tions including infection, inflammation, metabolic 
disorders, trauma, advanced age, etc., are associat-
ed with the accumulation of SF in the joint cavity. 
Laboratory testing of SF effusions is an additional 
and helpful tool for the diagnosis and classifica-
tion of disorders affecting the articular membrane 
(i.e. arthritides). The SF analyses with the highest 
clinical value are SF crystal detection in crystal-as-
sociated synovitis (gout and/or pseudogout), and 
SF total and differential cell count in the confirma-
tion of inflammatory (septic) arthropathies. Other 
biochemical analyses are neither specific nor sen-
sitive but might provide useful additional informa-
tion and narrow down the differential diagnosis of 
conditions affecting the joint. Combining the re-
sults of SF laboratory testing with the patient’s 
medical history and physical examination, arthritic 
disorders can be classified into four groups: non-
inflammatory, inflammatory, septic and haemor-
rhagic (2,8-12). Table 1 summarizes SF laboratory 
testing results associated with previously men-
tioned joint conditions (2,8,10-13).
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2. Preanalytical phase 
2.1 Patient preparation
No specific patient preparation procedure is 
needed before sample collection (arthrocente-
sis). If glucose is to be measured in the SF sam-
ple, the patient should be fasting at least 6 
hours prior to the SF collection (11). 
Since SF constituents mirror plasma concentra-
tions, the recommended fasting period is neces-
sary to equilibrate plasma and joint fluid concen-
trations in order to obtain reliable results of the SF 
analysis (8,11). 
2.2 Test request form and test ordering 
The test request form for synovial fluid labora-
tory testing should adhere to accreditation and 
good laboratory practice requirements. 
It should contain the patient’s name, surname, 
gender, date of birth and a unique identifier (e.g. 
health insurance number), collection date and 
time, collection location (hospital ward), identifi-
cation of the ordering physician and their con-
tact details, identification of the clinical staff that 
performed the collection. The diagnosis and 
tests requested should be clearly indicated. If the 
sample is to be analysed as urgent, this should be 
clearly indicated on the request (14).
2.3 Patient and sample identification
Samples should be labelled in the presence of 
the patient, with at least two unique identifiers 
(name and date of birth, preferably), location 
(ward), date and time of collection and anatom-
ic site of collection (e.g. left knee, right elbow) 
(15,16).
Improperly identified (or unlabelled) sample con-
tainers should not be accepted for analysis (15). 
Sample rejection should be documented by the 
laboratory and stated on the patient’s report. 
2.4 Synovial fluid collection and handling
Appropriate collection containers and sample 
handling procedures (transport and processing) 
should be directed by the test ordered and 
should reflect appropriate procedures used for 
the validated (standard) sample type (11). The 
recommended synovial fluid sample volume per 
container is 3-5 mL. Synovial fluid samples for bio-
chemical analyses should be collected in non-anti-
coagulated tubes (e.g. red top). Plain tubes with-
out additives (e.g. white top) are also acceptable. 
Synovial fluid for cell count, differential cell 
count, viscosity, and crystal analysis should be 
preferably collected in tubes containing liquid 
ethylenediaminetetraacetic acid (EDTA) (laven-
der top). Alternatively, plain tubes without addi-
tives are also acceptable (15-17).
Synovial fluid samples should be transported to 
the laboratory at room temperature immediately 
after collection (i.e. within one hour) in order to 
prevent cell degradation and alteration of bio-
chemical components. Refrigerated SF samples 
are not suitable for the crystal analysis since cool-
ing might induce in vitro precipitation of crystals. 
When necessary for interpretation purposes, a 
serum sample should be collected simultaneous-
ly to the arthrocentesis procedure (8,10,11,15). 
Synovial fluid is collected by arthrocentesis (i.e. 
aseptic needle aspiration from a joint) which is 
performed for diagnostic and therapeutic purpos-
es (11). This collection process is performed out-
side the laboratory and is coordinated as well as 
executed by trained clinicians. Efforts should be 
undertaken to standardize the SF collection pro-
cess since improper collection techniques could 
seriously impact SF test results (8,15,18). Aspira-
tions not performed according to standardized 
procedures increase the risk of causing blood ves-
sel damage, which can result in a haemolysed SF 
sample (19). Furthermore, the clinician performing 
the SF collection should be made aware if the pa-
tient is taking any medications. Available literature 
data suggests that arthrocentesis might be safely 
performed in patients receiving warfarin and di-
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rect oral anticoagulants without altering their anti-
coagulation regimen (20,21).  
Immediately after collection, an aliquot of the SF 
collected should be transferred to an appropriate 
container (tube). If anticoagulant containing tubes 
are used, they should be mixed gently according 
to the manufacturer’s instructions to ensure mix-
ing of anticoagulants and SF sample. These steps 
should be done at the site of the collection before 
transportation to the laboratory (15). 
The Clinical Laboratory Standards Institute (CLSI) 
recommends the following collection order: the 
first aliquot of the SF sample should be intended for 
biochemical analysis, the second aliquot for micro-
scopic examinations (cell count, differentials, and 
crystal identification), while the third should be in-
tended for microbiological analyses (2,8,15). The 
sample should be observed for clotting in case of 
non-anticoagulated tubes (normal SF does not clot, 
due to lack of fibrinogen). After clotting completion 
and centrifugation for 10 minutes, at 1000-3000 
rounds per minute (rpm), biochemical testing is per-
formed from the supernatant (9,10,15,19).
Tubes containing oxalate, lithium heparin or ly-
ophilised EDTA are not recommended, because 
they may form crystalline-resembling formations, 
which can be mistaken for monosodium urate 
(MSU) or calcium oxalate crystals, causing false 
positive results (2,10,15,19).
The volume of synovial effusion varies depending 
on the condition and the joint that is affected. Of-
ten during the collection procedure, it is not possi-
ble to obtain a valid amount of SF as recommend-
ed. Volumes of synovial fluid less than 1 mL, collect-
ed in tubes containing liquid anticoagulants, can 
result in the destruction of cell components. How-
ever, low volumes of SF collected in plain tubes 
should not be rejected by the laboratory because 
microscopic analysis (e.g. cell count, differentials) 
and crystals diagnostics are feasible from a few 
drops of the SF sample. If a recommended sample 
volume is not available, the clinician should prior-
itize the test requested according to the suspected 
diagnosis in collaboration with the laboratory 
(which acknowledges the sufficiency of the sample 
volume for the requested tests) (7,19).
Synovial fluid samples delivered to the laboratory 
for analysis in large syringes are generally not ac-
ceptable, especially regarding synovial fluid sam-
ple clotting (15). The practice of delivering SF sam-
ples to the laboratory in aspiration syringes (espe-
cially with needles) represents a potential biohaz-
ard and should be avoided. However, considering 
the peculiarities of this sample type and its collec-
tion procedure, the SF should not be rejected by 
the laboratory solely based on inadequate con-
tainer choice or non-compliant timeframe for sam-
ple delivery to the laboratory. Sample rejection cri-
teria should be instituted and followed; SF sample 
rejection should be documented by the laborato-
ry and stated in the patient’s report (8,15,19). 
2.5 Assessing sample quality
The quality of the sample should be assessed by 
visual inspection before analysis to avoid instru-
ment failures and/or measurement errors. Clot-
ted samples affect cell count accuracy and 
should not be considered suitable for these par-
ticular analyses. Inadequate sample quality 
should be documented in the test report (11,15).
Due to its high molecular weight, fibrinogen nor-
mally cannot pass through the synovial mem-
brane. The presence of fibrinogen in the SF will 
cause sample clotting and may indicate a traumat-
ic tap or a pathological disorder. To prevent sam-
ple clotting, an aliquot of the sample should be 
transferred in tubes containing liquid EDTA (8,11).
3. Method validation and quality control 
in synovial fluid laboratory testing
A peruse of the manufacturer’s performance 
specifications for methods used in SF analysis is 
a precondition prior to the determination of 
specific biochemical parameters in the SF. If per-
formance specifications for SF analysis are not 
provided in the manufacturer’s product insert, 
analytical method validation has to be under-
taken, accompanied with appropriate docu-
mentation. 
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Recommendations for method validation as 
well as quality control and proficiency testing in 
the EBF analysis are available in the first recom-
mendation of the WG EBFS and should be ap-
plied in the SF analysis (7,15).
4. Analytical phase 
Laboratory analysis of synovial fluid comprises of 
macroscopic examination (volume, appearance), 
the determination of specific biochemical analy-
ses, and microscopic examination (Figure 1). 
4.1 Macroscopic examination
4.1.1 Synovial fluid volume
The total volume of synovial fluid collected 
should be recorded by the clinician immediate-
ly after arthrocentesis on the test request form 
and should later be stated in the laboratory test 
report (10,19,22).
The accumulation of more than 3.5 mL of SF can 
be considered an abnormal volume, indicating an 
intra-articular process of different ethology (e.g. in-
flammatory). However, small SF volumes do not 
exclude a joint condition. The presence of parti-
cles like inclusion bodies or fibrin can lead to diffi-
culties in obtaining an SF sample, which might re-
sult in a falsely low volume collected (10,11,19,22).
4.1.2 Synovial fluid appearance
Synovial fluid appearance (colour and clarity) 
should be determined visually, upon sample re-
ceipt and before centrifugation (11). It should be 
stated on the test report. Although not specific, 
SF appearance might provide useful diagnostic 
information concerning joint inflammation and 
presence of haemarthrosis. Normal SF is colour-
less (yellowish) and clear (5,8,19). 
Synovial fluid appearance is an essential part of SF 
laboratory analysis. Synovial fluid appearance may 
Figure 1. Algorithm for synovial fluid laboratory analysis.
Synovial fluid analysis
1. Macroscopic examination of synovial fluid
(volume, appearance)
2. Biochemical analysis (glucose, lactate,
lactate dehydrogenase, uric acid, total proteins)
3. Cell count and microscopic synovial
fluid analysis (total and differential cell count,
crystal analysis)
indicate various disorders as well as a traumatic 
tap. If the SF is red-brownish and the colour is un-
evenly distributed, or a bloody stripe is noticed in 
the sample, a traumatic tap should be suspected 
(2,8,10,11,19). The clarity of SF might be modified 
by the presence of either increased numbers of 
white blood cells, or erythrocytes, synoviocytes, a 
multitude of MSU crystals, fibrin, cellular debris, li-
pids (e.g. in fat necrosis), chyle droplets, etc. 
(8,11,19). White free-floating rice-like aggregates, 
called rice bodies, may be present in SF samples. 
These particles are composed of collagen covered 
with fibrinous tissue and are frequently found in 
rheumatoid arthritis as a result of synovium de-
generation. Ochronotic shards may be also seen in 
SF samples. These appear like ground pepper par-
ticles and represent pigmented pieces of cartilage 
originating from ochronotic arthropathy or metal 
and plastic joint prosthesis (8,11,19). Macroscopic 
characteristics of SF fluid in health and different 
joint disorders are presented in Table 1.
4.1.3 Synovial fluid viscosity
The determination of synovial fluid viscosity is 
of low clinical value and should not be per-
formed routinely (8). 
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Regardless of its limited clinical significance, SF vis-
cosity is still assessed because of its cost-effective-
ness and simplicity. The degree of viscosity of the SF 
is assessed by the string test. The string test can be 
determined directly by the clinician while transfer-
ring the SF sample from the collection syringe to 
the appropriate container. Alternatively, the string 
test can be performed before centrifugation by lab-
oratory staff placing one drop of synovial fluid be-
tween two gloved fingers, a thumb, and an index 
finger. By moving fingers slowly in the opposite di-
rection, a 5-centimetre-long string should be 
formed between them before breaking. If the string 
formed is < 3 centimetres long (low viscosity), it 
might suggest an ongoing inflammatory process in 
the joint. A string longer than 6 centimetres is found 
in cases of septic arthritis. Although accurate meas-
urements of SF viscosity can be performed using s 
viscometer, this is rarely performed due to the low 
clinical value of this parameter (11,19).
Synovial fluid viscosity is physiologically very high 
and depends on the amount of polymerized hya-
luronate present. Normal SF has a hyaluronate 
concentration of 3.0–3.5 g/L. These concentrations 
decrease physiologically after the age of 50, and at 
about the age of 80, their values are approximate-
ly 2 g/L. Furthermore, hyaluronate can be depo-
lymerized by the hyaluronidase present in neutro-
phils and bacteria during inflammatory conditions 
of the joint. Additionally, some conditions prevent 
the synthesis of hyaluronate by synoviocytes. The 
result is a decreased (low) viscosity of the SF indi-
cating the presence of an inflammatory process in 
the joint. The protein SF content, as well as the 
protein type, cells, temperature, and enzymes, 
have an impact on the SF viscosity (8,10,11,18, 
19,22,23).
4.1.4 Synovial fluid mucin test
Although the SF mucin (also called the Rope’s) 
test is an indirect measure of SF viscosity, it is 
considered obsolete and should not be per-
formed routinely (8).
Parameter Normal SF Non-inflammatory SF Inflammatory SF Septic SF Haemorrhagic SF





Lightly yellowish – 










Leukocyte count, x106/L < 200 20–2000 2000–50,000 > 50,000 Equal to blood
































SF – synovial fluid. Glucose difference – the difference of glucose concentrations between serum and SF, when serum samples are 
collected simultaneously. SLE – systemic lupus erythematosus. Adapted from (2,8,10-13).
Table 1. Classification of joint effusions according to SF laboratory testing
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The mucin clot test is a qualitative test that esti-
mates the degree of polymerization of the hyalu-
ronic acid-protein complex (mucin) responsible for 
SF viscosity. It provides little diagnostic informa-
tion, but it is still used by some laboratories be-
cause of its simplicity. Mucin test can be per-
formed to differentiate the synovial fluid from oth-
er fluids of uncertain origin (8,11,19).
4.2 Biochemical synovial fluid analysis 
Biochemical and microscopic analysis of SF sam-
ples should be performed immediately upon 
sample receipt (i.e. within 2 hours after collec-
tion) to avoid unreliable results. The first tube 
collected without additive should be inspected 
for clotting and then centrifuged to remove cel-
lular and other components. The supernatant is 
used for chemical analyses. Very viscous synovi-
al fluid samples should be pre-treated with a 
hyaluronidase solution to reduce sample viscos-
ity, and then analysed. Biochemical analyses of 
the SF considered clinically useful are described 
below (10,11,15,23,24).  
Synovial fluid has a similar chemical composition 
to plasma, although the concentrations of ana-
lytes found in normal SF are mostly lower com-
pared to those found in the blood. Higher analyte 
concentrations are often related to intra-articular 
alterations and pathologic conditions. 
Delayed laboratory analysis of SF samples might 
cause a reduction of the leukocyte number pre-
sent in the sample; which is more pronounced in 
samples with higher leukocyte counts. Further-
more, prolonged sample storage (at room temper-
ature or refrigerated) after collection might cause 
the artefactual formation and/or dissolution of 
crystals and the alteration of their optical charac-
teristics. Thus, delayed analysis of SF samples 
could lead to the misdiagnosis of the underlying 
joint condition (10,23). 
Different protocols for hyaluronidase solution 
preparation are available (e.g. 25 mg hyaluroni-
dase and 1 mL of SF are incubated at 37ºC for 5 
minutes, or 0.5 mg lyophilized hyaluronidase pow-
der and 1 mL of SF incubate 15 minutes at room 
temperature) (19,25). A laboratory can also prepare 
plain microcentrifuge tubes with added hyaluroni-
dase solution in advance and store them in a re-
frigerator or freezer prior to analysis. It is impor-
tant in this course of action not to forget to calcu-
late the dilution effect of hyaluronidase solution. 
Each laboratory should select the most suitable 
protocol for a routine application. 
4.2.1 Synovial fluid glucose
Synovial fluid glucose should be interpreted ac-
cording to simultaneous glucose concentrations 
measured in the serum. Standard (serum) pro-
cedures should be applied to synovial fluid glu-
cose measurement. Glucose concentrations in 
SF should be determined within one-hour form 
collection in order to prevent erroneously low 
glucose concentrations due to the glycolytic ac-
tivity of leukocytes in the sample (8,10,11).
A simultaneous analysis of glucose concentrations 
in the serum and SF enables more reliable inter-
pretation of glucose concentrations in the SF sam-
ple. In the fasting state glucose concentrations in 
the serum and SF are equivalent and the serum-
synovial fluid glucose difference is ≤ 0.6 mmol/L. 
Conversely, in non-fasting patients, the serum-
synovial fluid difference is > 0.6 mmol/L. Non-in-
flammatory and haemorrhagic conditions affect-
ing the joint are characterized by a serum-synovial 
fluid glucose difference of < 1.1 mmol/L (Table 1). 
In inflammatory, crystal-induced and infectious 
joint conditions the serum-synovial fluid glucose 
difference is up to 2.2 mmol/L, 4.4 mmol/L, and 
1.1–5.6 mmol/L, respectively. According to the Cro-
atian Chamber of Medical Biochemistry (CCMB), 
the reference range for glucose in SF samples is 
3.3–5.3 mmol/L (8,11,15,26).
4.2.2 Synovial fluid lactate
The value of lactate measurement in SF is un-
certain. Consequently, it should not be meas-
ured routinely. Synovial fluid lactate might be 
measured in case of suspected bacterial (septic) 
arthritis (8,11,15).
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The measurement of lactate concentrations in SF 
is a helpful tool in the diagnosis of septic arthritis, 
especially in cases of negative bacteriologic cul-
ture results. The reference range for lactate con-
centrations in SF samples is 1.0–1.8 mmol/L. How-
ever, lactate concentrations increase with an in-
creasing severity of inflammation, reaching con-
centrations as high as 13.5 mmol/L in culture posi-
tive SF samples. Lactate concentrations greater 
than 9.0 mmol/L strongly support the diagnosis of 
bacterial arthritis indicating the need for immedi-
ate treatment (8,11,15,26).
4.2.3 Synovial fluid uric acid
The determination of uric acid in SF samples 
should be performed in cases of suspected 
gout without increased plasma uric acid con-
centrations, without urate crystals present mi-
croscopically or in laboratories without the nec-
essary equipment for MSU crystal analysis 
(8,11,15).
The diagnosis of gout is established by the pres-
ence of patient’s symptoms and by measuring uric 
acid in plasma. The diagnosis is confirmed by the 
finding of MSU crystals in the SF. The determina-
tion of uric acid in SF samples is a helpful addition-
al tool in gout diagnosis and should be measured 
using standard laboratory methods. Since SF uric 
acid concentrations are equivalent to those found 
in the, they are generally monitored by serum 
measurements (8,11,15). 
4.2.4 Synovial fluid total proteins
Synovial fluid proteins should be routinely 
measured in SF samples with standard (serum) 
procedures. The reference range of total proteins 
in SF samples is 11–22 g/L. Higher total protein 
concentrations are a nonspecific indicator of the 
presence of inflammatory joint disorders and are 
of little value in the differentiation of joint disor-
ders or in guiding treatment (11,25-27).
Although all plasma proteins can be found in SF, 
high-molecular-weight proteins (e.g. α2-macro-
globulin, β2-macroglobulin, and fibrinogen) are 
present only in very low concentrations or com-
pletely absent. Total protein concentrations in nor-
mal SF are about 1/3 of the protein concentration 
in plasma. The increased protein concentrations 
are caused by increased permeability of the syno-
vial membrane or by increased synthesis in the 
joint cavity. Albumin represents the main protein 
fraction in SF with concentrations of approximate-
ly 12 g/L. The presence of ankylosing spondylitis, 
arthritis, arthropathies that appear as secondary 
consequences of Crohn disease, gout, psoriasis, ul-
cerative colitis, etc., are accompanied by high total 
SF protein concentrations (8,10,11,26,27).
4.2.5 Synovial fluid rheumatoid factor
Synovial fluid rheumatoid factor (RF) should not 
be routinely determined as a part of SF analysis. 
It might be determined as a confirmatory analy-
sis in cases of rheumatoid arthritis (RA) that are 
not definitively diagnosed by standard (serum) 
analyses (10,28-30). 
Synovial fluid RF can be found in approximately 
60% of patients with RA in slightly lower concen-
trations than those found in serum (≤ 14 IU/mL). In 
general, synovial fluid RF determination in RA is 
not considered to be diagnostically helpful be-
cause positive RF may simply reflect serum con-
centrations and might derive from other chronic 
inflammatory conditions (19,28).
4.2.6 Synovial fluid C - reactive protein
Synovial fluid C-reactive protein (CRP) should 
not be routinely measured to assess inflamma-
tion in the joint. However, SF CRP has demon-
strated high sensitivity and specificity for the di-
agnosis of periprosthetic joint infection (PJI) and 
might be measured in patients with previous 
joint replacement and high clinical suspicion of 
PJI (10,31).
Nowadays, along with the CRP, human alpha-de-
fensin 1-3 (AD) can be used for the diagnosis of PJI. 
Alpha-defensin has shown high diagnostic sensi-
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tivity and specificity for suspected PJI, especially 
after total knee and hip arthroplasty. The useful-
ness of AD has been demonstrated in ruling out 
PJI and it could be used as a confirmatory test for 
PJI (32-35).
4.2.7 Synovial fluid lactate dehydrogenase
The activity of lactate dehydrogenase (LD) in SF 
samples should be measured as an indicator of 
the inflammation level present in the joint. The 
reference range of LD in SF is < 280 U/L (11,26).
Lactate dehydrogenase is the enzyme most fre-
quently determined in SF samples. In normal SF, 
LD activity is lower compared to LD plasma activi-
ty. However, LD activities might be higher in SF 
samples, while normal activities are present in 
plasma. Lactate dehydrogenase activities of 400-
700 U/L are related to moderate rheumatoid ar-
thritis activity, while those exceeding 750 U/L indi-
cate a high inflammatory activity. In general, high 
LD activities (i.e. above 280 U/L) are found in in-
flammatory effusions (e.g. gout, infectious arthri-
tis, rheumatoid arthritis) (11,15,26). 
4.3 Cell count and microscopic synovial fluid 
analysis
4.3.1 Total and differential cell count in synovial fluid
Total and differential cell counts should be per-
formed promptly upon the receipt of the SF 
sample (i.e. within one hour from the collection) 
using automated methods (analysers with a 
suitable mode for body fluid analysis). Alterna-
tively, total and differential SF cell counts might 
be determined manually (by means of light mi-
croscopy). The normal SF total white blood cell 
(WBC) count is < 200 x106/L. Manual differential 
WBC count should be performed in a stained 
cytocentrifuged preparation which allows the 
identification of cell types with diagnostic impli-
cations. The predominant cells found in SF are 
lymphocytes, monocytes, and macrophages, 
with a few neutrophils and synovial lining cells. 
The normal value of SF polymorphonuclear leu-
kocytes (%PMN) is < 10%.
Although total WBC count and differentials 
have limited value in identifying specific joint 
conditions due to considerable intra-individual 
variations, it is accepted in clinical practice that 
the WBC count and %PMN moderately correlate 
with the degree of joint inflammation 
(3,5,8,10,11,18).
The white blood cell count and differential count 
are basic tools in the diagnosis and differentiation 
of various inflammatory and non-inflammatory 
conditions of the joint. Since the total WBC count 
gives overlapping results in the differentiation of 
joint disease categories in practice, the combina-
tion of WBC count and %PMN can be used to bet-
ter discriminate non-inflammatory, inflammatory 
and infectious joint disorders. Differentials with 
%PMN > 80% are associated with bacterial arthritis 
and urate gout, while increased lymphocyte 
counts often occur in early stages of RA. The lack 
of harmonization of cell counting and differentia-
tion presents a clear limitation in determining 
unique cut-offs for the diagnosis of various joint 
conditions. According to the American Rheuma-
tism Association, the cut-offs for total WBC count 
and %PMN are as follows: 
(a) normal SF - WBC < 200 x106/L, PMN < 25%; 
(b) non-inflammatory SF - WBC < 2000 x106/L, PMN 
< 25%; 
(c) inflammatory SF - WBC 2000–50,000 x106/L, 
PMN > 50%;
(d) infectious SF - WBC > 50,000 x106/L, PMN > 75% 
(Table 1) (3,10,13,18).
Available literature data suggest that anti-inflam-
matory drugs, especially nonsteroidal anti-inflam-
matory drugs (NSAIDs), in general, do not affect 
the total cell count in SF samples, although NSAIDs 
reduce the function of white blood cells (e.g. the 
production of proinflammatory cytokines) (36,37). 
However, in general, information concerning the 
intake of medications can be noted on the labora-
tory test request. 
The presence of synovial lining cells is of no clinical 
significance. Abnormal numbers of cells or atypi-
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cal cell types (i.e. plasma cells, eosinophils, lupus 
erythematosus cells, malignant) are indicative of 
various conditions affecting the joint (8,11). Syno-
vial fluid samples with atypical cell types should 
be referred to cytological evaluation. 
The total WBC with differentials should be per-
formed within one hour of the collection to avoid 
cell destruction. However, accurate results can be 
obtained if SF samples are stored at 2-8°C in tubes 
containing EDTA additive (38,39). The undiluted SF 
sample should be thoroughly mixed prior to anal-
ysis. If significantly turbid, SF samples should be 
diluted with isotonic saline. Inflammatory SF fluids 
are prone to visible clotting, which might affect 
accurate cell count determination. Such SF sam-
ples should be analysed immediately or collected 
in tubes with appropriate additives. Erythrocytes 
have limited diagnostic value in SF samples. A high 
number of erythrocytes present in the SF sample 
derives either from haemorrhagic effusions or 
traumatic arthrocentesis. A high erythrocyte num-
ber might interfere with the WBC count and differ-
ential count. Consequently, erythrocytes should 
be selectively lysed by diluting the sample using 
hypotonic saline (0.3%) (8,10,22,39). 
Manual cell counts in SF samples are performed 
using a haemocytometer (Neubauer or Fuchs- 
Rosenthal chamber). Due to SF sample’s high vis-
cosity, the cells should be allowed to settle in the 
chamber for an additional period of time before 
counting. If necessary, sample viscosity should be 
reduced by dilution with hyaluronidase buffer en-
abling a more homogeneous cell distribution in 
the counting chamber (8,10).
Differential cell count should be performed by 
staining air-dried smears of cytocentrifuged SF 
samples according to May-Grünwald or Wright. 
Leukocyte morphology is then assessed under 
high power light microscope using oil immersion. 
Usually, mononuclear cells are predominant in 
non-inflammatory disorders while polynucleated 
cells prevail in inflammatory processes (12,26,39).
Although still considered the reference technique 
for counting and differentiation, optical microsco-
py is technically challenging, has a low throughput 
which results in longer turnaround times (TAT), is 
prone to substantial intra- and inter-observer vari-
ations and lacks standardization. Modern auto-
mated haematology analysers adapted for the SF 
counting analysis offer technical and clinical ad-
vantages. Compared to manual methods, auto-
mated counting is more reliable and practical, re-
duces TAT and enables longer cell stability. How-
ever, the limitations of automated cell counting 
methods should also be addressed, especially 
their inability to detect or correctly classify malig-
nant cells and atypical leukocytes, their high im-
precision (especially in samples with low cell 
counts), the interference of non-cellular particles 
(e.g. fat globules, cartilage fragments, crystals) 
which may cause pseudoleukocytosis or pseudoe-
osinophilia, and the presence of possible matrix 
effect which might affect proper sample aspira-
tion. Therefore, unclear automated results, SF sam-
ples with low WBC count, suspected malignant 
samples, as well as suspected interferences should 
be verified by manual microscopy (3,5,7,8,13,40).
4.3.2 Synovial fluid crystals
The presence of MSU is pathognomonic for 
urate arthritis (gout), while calcium pyrophos-
phate dihydrate (CPPD) crystals are associated 
with chondrocalcinosis (pseudogout). Synovial 
fluid crystal analysis should be performed using 
(direct or compensated) polarizing light micros-
copy (PLM). Slides should be prepared using cy-
tocentrifuged SF samples to increase the sensi-
tivity of crystal detection (5,8,11,12,18).
The identification of crystals by PLM is one of the 
most important analyses performed in SF sam-
ples. It is considered the gold standard for the 
definitive diagnosis of gout and pseudogout, es-
pecially in atypical cases. Compensated polariz-
ing microscopy is the standard method for crys-
tal identification. It allows the differentiation of 
synovial fluid crystals based on their birefrin-
gence. Synovial fluid crystals have the ability to 
refract polarized light in two dimensions at 90 
degrees to each other and, depending on their 
molecular structure, to produce a characteristic 
colour under compensated polarized light. The 
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a) it requires more time to prepare the slide; b) it 
requires special equipment (cytocentrifuge); and 
c) in the presence of a large number of cells, the 
identification of crystals is more difficult. Alterna-
tively, in the absence of a cytocentrifuge, slides for 
microscopic crystal analysis can be prepared using 
a conventional centrifuge, centrifuging samples 
for 10 minutes at 700 rpm (8,46).
Wet slides for SF crystal analysis are prepared from 
native samples. One drop of a thoroughly mixed 
SF sample is placed on a slide and covered with a 
coverslip. The sample should fill the area under 
the coverslip. The differentiation of SF crystals is 
difficult because their number might vary signifi-
cantly; they are very similar, may be hidden in fi-
brin or cellular debris, and may be mistakenly 
identified as artefacts. Therefore, slides should be 
examined by experienced laboratory personnel. 
Slide examination should start with a low-power 
field screening procedure (100x magnification) fol-
lowed by the identification of crystals using a 
high-power field (HPF) magnification (400x or 
higher). A crystal positive sample of the SF should 
contain at least two typical shapes (e.g. MSU nee-
dle-like shape) in each field of 10 randomly select-
ed fields of view. Crystals description should in-
clude birefringence (strong, weak), shape (needle, 
rhomboid, square bipyramidal, etc.), cell location 
(intra-, extracellular) and quantity (number of crys-
tals as per HPF) (8,10,22,25,40).
compensator separates the light beam into slow- 
and fast-moving vibrations and produces a red 
background. Monosodium urate crystals are 
highly negatively birefringent and appear yellow 
when aligned with the slow vibrations, while 
CPPD is positively birefringent producing a blue 
colour (10,41,42). 
Various types of crystals might be found in SF, two 
of the most frequent being MSU and CPPD. Other 
crystals (e.g. calcium hydroxyapatite, cholesterol, 
steroid crystals) have pathologic significance in 
the diagnosis of crystalline joint conditions (Table 
2) (5,8,10,11,43).
The temperature and variations in pH can affect 
crystal formation and solubility. Therefore, crystal 
analysis should be performed at room tempera-
ture as soon as possible after arthrocentesis 
(8,10,22). If MSU and CPPD crystal analysis are to be 
delayed or for educational purposes, the SF sam-
ple might be stored at room temperature (with or 
without sodium heparin or EDTA) up to 72 hours 
or at 4°C for eight weeks (5,18,24,43).
The cytocentrifugation prior to crystal analysis has 
several advantages: a) it concentrates SF compo-
nents in a monolayer increasing sensitivity and re-
covery; b) the slides prepared might be retained 
for education, training and competency assess-
ment; and c) the slides might be examined under 
microscope stained or unstained (8,44,45). Never-
theless, cytocentrifugation has several limitations: 
Crystal Joint condition Microscopic characteristics
Monosodium urate Urate arthritis (gout) Fine, needle-like with strongly birefringent; extra- or intracellular (in leukocytes)
Calcium 
pyrophosphate
Chondrocalcinosis (pseudogout), degenerative 
arthritis, arthritis accompanying metabolic diseases
Rod-like, rhomboid, squared with a weak 
birefringence (best visualized by light microscopy)
Cholesterol Chronic inflammatory conditions (RA) Flat, rectangular plates, not birefringent
Hydroxyapatite Apatite-associated arthropathies Tiny, needle-like, not birefringent, present in leukocytes and visible only by electron microscopy
Corticosteroid Months after intra-articular injection
Variable depending on the corticosteroid 
applied, similar to monosodium urate or calcium 
pyrophosphate
RA – rheumatoid arthritis. Adapted from (8,10,11,22,24).
Table 2. Synovial fluid crystals in joint conditions
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5. Postanalytical phase 
Laboratory test reports of SF analysis should in-
clude the type of fluid analysed, the measured 
value, as well as reference range and/or decision 
limits for each tested analyte in order to guide 
clinical interpretation and decision-making. Ad-
ditionally, test reports should include a com-
ment acknowledging the possible influence of 
sample matrix on the test’s accuracy and thus 
the need to interpret results in conjunction with 
clinical symptoms (7,15). If methods used in SF 
analysis have not been validated in the labora-
tory, a comment should be included on the test 
report. Furthermore, the laboratory should con-
tact the ordering physician prior to issuing such 
laboratory test reports to explain potentially in-
fluencing factors. Laboratories are strongly en-
couraged to communicate and comment the 
results obtained by SF analysis with the order-
ing/responsible clinical personnel in order to 
aid diagnosis, better patient management or 
recommend further laboratory testing. Stand-
ardized interpretive comments should be in-
cluded in the SF analysis test reports (7,15,47,48).
The results of SF biochemical analysis should be 
reported in the same units as those obtained in 
the serum/plasma. The values of simultaneous 
measurement of an analyte in the serum/plasma 
and synovial fluid (e.g. glucose) should be report-
ed on the same test report (15,48). Decision limits 
and/or reference intervals for clinically useful ana-
lytes in SF laboratory testing are provided 
throughout this document and should be imple-
mented on the test report (summarized in Table 3). 
Similarly, the recommended storage conditions 
might be applied, although laboratories should 
validate the stability of the analytes tested in SF 
samples in their own routine setting (7,15).
The test report should include interpretive com-
ments addressing the preanalytical and analytical 
phases of SF analysis. If available, a laboratory in-
formation system should be used to generate 
standardized and clear comments (7). The practice 
of directly communicating and interpreting results 
with the ordering/responsible clinician should be 
encouraged.
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Parameter Normal SF Inflammatory SF Septic SF
Glucose (mmol/L) 3.3–5.3 1.1–3.1 1.1–1.7 
Lactate (mmol/L) 1.0–1.8 Up to 6.8 > 9.0
Uric acid (mmol/L) Equal to blood Equal to blood Equal to blood
Total proteins (g/L) 11–22 > 40 30–60 
RF Negative Positive/negative Negative
LD (U/L) < 280 > 280 (to 750) > 300
WBC (x106/L) < 200 2000–50,000 50,000 
%PMN < 25 > 50 > 75
Monosodium urate crystals Negative Positive Negative
Calcium pyrophosphate crystals Negative Positive Negative
SF – synovial fluid. RF – rheumatoid factor. LD – lactate dehydrogenase. WBC – white blood cell count. PMN – polymorphonuclear 
lymphocytes. Adapted from (2,8,10,12,13,15,19,26).
Table 3. Reference intervals and differential limits for clinically useful analytes
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